AGP Picks
View all

Zephyrus says VaporShield drew strong response in pre-commercial hospital workshops

Nov. 16, 2026
Zephyrus says VaporShield drew strong response in pre-commercial hospital workshops
By AI, Created 10:24 UTC, Nov 16, 2026, AGP -

Zephyrus Innovations says it completed pre-commercial VaporShield training workshops and product evaluations across key U.S. hospital accounts ahead of commercialization. More than 50 healthcare professionals took part, and the company says all surveyed users thought the system would provide better protection than current devices.

Why it matters: - Zephyrus Innovations is pushing VaporShield toward commercialization after testing the system with hospital buyers and clinical staff. - The results matter because the product targets hazardous drug handling, where healthcare workers want stronger protection from splashing, spraying and aerosolization. - The company is positioning VaporShield for future commercial pilot programs in the U.S.

What happened: - Zephyrus Innovations completed pre-commercial VaporShield CSTD training workshops and product evaluations across several key U.S. strategic hospital accounts. - The workshops took place during the first week of November 2026 at hospitals and cancer centres in Ohio. - More than 50 pharmacists, medication safety officers, nurse administrators and other healthcare professionals participated. - Zephyrus said the program included educational presentations, product demonstrations and hands-on evaluations.

The details: - Zephyrus describes VaporShield as the world’s first direct injection CSTD for subcutaneous and intramuscular administration. - The company says VaporShield is an end-to-end closed system designed to prevent splattering, spraying and aerosolization of drugs. - In survey feedback shared by Zephyrus, 100% of respondents said VaporShield would offer better protection than current devices. - Tom Crockett, head of sales and marketing, said the feedback was overwhelmingly positive and that users said they would be happy to introduce the innovation into clinical practice. - Will Wijnberg, chief executive officer, said the workshops helped the company demonstrate the product, listen to healthcare professionals and understand their needs. - Wijnberg said Zephyrus is moving toward commercial pilot programs in the next few weeks. - Zephyrus is a privately owned medical device company that designs and manufactures safety syringes and closed system transfer devices. - The company says its products are designed to help protect clinicians from harmful drug exposure and needlestick injuries.

Between the lines: - The Ohio workshops suggest Zephyrus is using early clinical engagement to build credibility before a wider launch. - Interest around USP<800> compliance appears to be an important sales angle as hospitals look for stronger hazardous-drug handling protections. - The 100% survey result is a strong signal, but it comes from a small, company-run evaluation group rather than a large independent study.

What's next: - Zephyrus plans to move VaporShield into commercial pilot programs. - The company says it will continue engaging healthcare professionals as it advances toward full commercialization. - More information is available at the company's announcement and by email at info@zephyrusinnovations.com.

The bottom line: - Zephyrus is turning early hospital feedback into launch momentum, and VaporShield’s next test is whether that enthusiasm holds in broader clinical use.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Healthcare Online Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthcare Online Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.